U.S. markets open in 22 minutes

Cosmos Holdings Inc. (COSM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.78000.0000 (0.00%)
At close: 11:35AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.7800
Open4.7800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.7800 - 4.7800
52 Week Range1.1500 - 5.7900
Volume10
Avg. Volume1,768
Market Cap61.376M
Beta (5Y Monthly)1.29
PE Ratio (TTM)36.77
EPS (TTM)0.1300
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cosmos Holdings Launches Osteodome in EU
    GlobeNewswire

    Cosmos Holdings Launches Osteodome in EU

    COSMOS HOLDINGS LAUNCHES OSTEODOME IN EU New Proprietary Dietary Supplement Contributes to Normal Bone and Cartilage Health and Joint Flexibility New Proprietary Dietary Supplement Contributes to NormalBone and Cartilage Health and Joint Flexibility Osteodome Is Second Product to Be Marketed throughout the UKDuring First Quarter 2021 EU Distribution Network Grows to 1500 Pharmacies with Access to Additional 50,000 CHICAGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the company") (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, announced today the launch of a new, proprietary enhanced dietary supplement, Osteodome. Osteodome is a targeted nutritional supplement specifically designed to support normal bone and cartilage function and joint flexibility. Osteodome contains glucosamine, chondroitin, MSM, Hyaluronic Acid, turmeric, green tea, olive tree extracts, vitamins C, D3, K2, manganese, zinc and other minerals. It is one of the newest offerings in the Sky Premium Life line of luxury nutritional supplements. Like all other Sky Premium Life products, Osteodome is made with the highest quality raw materials and to the highest possible standards, which are, in turn, based on strict pharmaceutical standards and good manufacturing processes (GMP) protocols; these protocols are similar to FDA regulations in the USA. The supplement was formulated, designed and developed entirely by the Cosmos Holdings research and development team. “Our research and development team has been working all year to develop additional nutraceuticals and supplements for the EU market,” Mr. Siokas continued. “Osteodome is one of a number of products Cosmos will introduce to this market throughout 2021. We expect Osteodome and other nutraceuticals and supplements to contribute substantially to our growth and profitability in 2021.” Osteodome contributes to: • normal bone and cartilage function• supporting joint flexibility• the normal formation of collagen in the body• the normal formation of connective tissue in the body• the normal muscle functions• the normal absorption of calcium and phosphorus• the protection of cells from oxidative stress (antioxidant) “Our research and development team has created unique formulas, with vitamins and herbs, that support specific health needs, a luxury line made with the finest materials, along with a wide range of basic premium quality supplements,” said Greg Siokas, Chief Executive Officer of Cosmos Holdings. “These products promote health and well-being, which we believe are especially important during the Covid-19 pandemic. Sky Premium Life products are available throughout Europe, via our established distribution network, which we have built through relationships with 160+ pharmaceutical wholesale distributors in Europe’s largest markets. We also sell Sky Premium Life supplements directly to 1,500 pharmacies, with access to more than 50,000 pharmacies throughout Europe, and we are of course looking beyond Europe.” On January 11, 2021, Cosmos Holdings announced the launch of a new, proprietary enhanced dietary supplement, Bodyguard, a targeted action formula for strengthening the immune system and reducing fatigue. On November 25, 2020, the company announced the beginning of trading on the OTCQX Best Market. On November 18, 2020, Cosmos Holdings announced its Third Quarter and Nine-Month financial results. About Cosmos Holdings, Inc. Cosmos Holdings Inc., is an international pharmaceutical company, with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices and an extensive, established EU distribution network. The company identifies, acquires, develops and commercializes products that improve patients' lives and outcomes. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and Harlow, UK. Press Release Disclaimer Cosmos Holdings, Inc. takes no responsibility for updating the information contained in this press release, following the date hereof, to reflect events or circumstances occurring after the date hereof, or the occurrence of unanticipated events, or for any changes or modifications made to this press release, or the information contained herein by any third parties, including, but not limited to, any wire or internet services. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could”, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the company, including, but not limited to, the company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers, are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Michael J. Porter, PresidentPorter, LeVay & Rose, Inc.T: (973) 865-9357E: mike@plrinvest.comLinkedIn@PlRinvest A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/7d41f2dc-7889-41ca-a2da-b6e1282618ed

  • Cosmos Holdings Launches New Proprietary Enhanced Dietary Supplement
    GlobeNewswire

    Cosmos Holdings Launches New Proprietary Enhanced Dietary Supplement

    Cosmos Holdings Introduces New Proprietary Enhanced Dietary Supplement Sky Premium Life Bodyguard: Strengthens Immune System and Reduces Fatigue Supplements to Be Distributed throughout the EU Cosmos Holdings Launches New Proprietary Enhanced Dietary Supplement Sky Premium Life SupplementsCHICAGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the company") (OTCQX: COSM), a vertically integrated international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, today announced the launch of a new, proprietary enhanced dietary supplement, Bodyguard, a targeted action formula for strengthening the immune system and reducing fatigue. Designed and developed by the company’s wholly owned pharmaceutical subsidiary, Doc Pharma S.A., which was founded in Thessaloniki, Greece, in 2015, Bodyguard, which contains Sambucus (elderberry), beta-glucans, vitamin C, zinc, D3, K2 B12, Selenium and Copper, is the newest offering in the Sky Premium Life line of luxury nutritional supplements. Bodyguard, similar to all Sky Premium Life products, is made with the highest quality raw materials and to the highest possible standards, which are in turn based on strict pharmaceutical standards and GMP protocols.Sambucus, or Elderberry, is a plant known in traditional medicine since antiquity; beta-glucans, are a type of fiber in the form of polysaccharides and are usually derived from plant sources (barley, oats) or from certain types of mushrooms. Vitamin C and Zinc are known to be important factors for the proper functioning of the immune system.Sky Premium Life Bodyguard: * contributes to the normal functioning of the immune system * enhances the body’s energy levels * reduces fatigue and tiredness * acts as an antioxidant to protect cells“We have created unique formulas, with vitamins and herbs, that support specific health needs, a luxury line made with the finest materials, along with a wide range of basic premium quality supplements,” says Greg Siokas, Chief Executive Officer of Cosmos Holdings. “These products promote health and well-being, which we believe are especially important during the Covid-19 pandemic. Sky Premium Life products are available throughout Europe, via our established distribution network, which we have built through relationships with 160+ pharmaceutical wholesale distributors in Europe’s largest markets; we also sell Sky Premium Life supplements directly to 1,500 pharmacies, with access to more than 50,000 pharmacies throughout Europe, and we are looking beyond Europe, as 2021 approaches.”“Our research and development division has been working all year to develop additional nutraceuticals and supplements for the EU market,” Siokas continued. “Bodyguard is the first, of a number of products, Cosmos will introduce to this market throughout 2021. We expect Bodyguard, and other nutraceuticals and supplements, to contribute substantially to our growth and profitability in 2021.”Cosmos Holdings will launch a dynamic advertising campaign for Bodyguard, including television with a high-end animation spot, listings in international branded lifestyle magazines like Harper’s Bazaar, Madame Figaro and Vogue, industry magazines, newsletters, advertorials, digital campaigns in social media and via Google AdWords.On November 25th, 2020, Cosmos Holdings announced the beginning of trading on the OTCQX Best Market. On November 18th, 2020, the company announced its Third Quarter and Nine-Month financial results.About Cosmos Holdings, Inc.Cosmos Holdings Inc. is an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices and an extensive, established EU distribution network. The company identifies, acquires, develops and commercializes products that improve patients' lives and outcomes. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and Harlow, UK.Press Release DisclaimerCosmos Holdings, Inc. takes no responsibility for updating the information contained in this press release, following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third parties, including, but not limited to, any wire or internet services.Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the company, including, but not limited to, the company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor RelationsMichael J. Porter, President Porter, LeVay & Rose, Inc. T: (973) 865-9357 E: mike@plrinvest.com LinkedIn @PlRinvestCosmos Holdings +1 312 536 3102 info@cosmoshold.com 141 West Jackson Blvd., Suite 4236 CHICAGO, IL 60604Photos accompanying this announcement are available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/a04f4aa9-e3f6-4c01-88d5-a4bebb74718dhttps://www.globenewswire.com/NewsRoom/AttachmentNg/14905889-7c43-4542-b8fc-4b31c327e05b

  • Cosmos Holdings Announces December 4th Virtual Bell Ringing to Open Trading on the OTCQX Best Market
    GlobeNewswire

    Cosmos Holdings Announces December 4th Virtual Bell Ringing to Open Trading on the OTCQX Best Market

    Company Began Trading as OTCQX: COSM on November 25, 2020CHICAGO, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the company") (OTCQX: COSM), a vertically integrated international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, participated in a virtual “Open the Market” on the OTCQX® Best Market today at 9:30 a.m. EST. The virtual bell ringing can be viewed on the OTCQX Best Market social media channels: https://twitter.com/OTCMarkets/status/1334867689333026816?s=20https://www.linkedin.com/feed/update/urn:li:activity:6740633309879029761Cosmos Holdings, Inc. began trading on the OTCQX on November 25, 2020. The company was upgraded to OTCQX from the OTCQB® Venture Market. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.About Cosmos Holdings, Inc.Cosmos Holdings Inc. is an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices and an extensive, established EU distribution network. The company identifies, acquires, develops and commercializes products that improve patients' lives and outcomes. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and Harlow, UK.Press Release DisclaimerCosmos Holdings, Inc. takes no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services.Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the company, including, but not limited to, the company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor RelationsMichael J. Porter, President Porter, LeVay & Rose, Inc. T: (973) 865-9357 E: mike@plrinvest.com  LinkedIn @PlRinvestCosmos Holdings +1 312 536 3102 info@cosmoshold.com  141 West Jackson Blvd., Suite 4236 Chicago, IL 60604